Summary
The product PRIMOS 100 mg/ml, manufactured by Driada Medical, underwent laboratory testing to verify its composition and potency. The analysis, conducted by Janoshik Analytical, confirmed the presence of methenolone enanthate at a concentration of 97.03 mg/ml, closely aligning with the labeled claim of 100 mg/ml. This reflects a minor variance of 2.97% below specification, indicating the product is accurately dosed within acceptable limits.
Testing began on 6 January 2022, with the sample received on 7 January 2022, and the analysis concluded on 9 January 2022. The sample was submitted and funded by Driada Medical, necessitating careful interpretation of the results due to the potential for bias. This report is published for harm reduction and educational purposes, aiding consumers in making informed decisions.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: PRIMOS 100 mg/ml
- Active Ingredient: Methenolone Enanthate
- Batch Number: 483301
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #16178
- Testing Ordered: 6 January 2022
- Sample Received: 7 January 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 100 mg/ml (as stated on the label)
- Measured Concentration: 97.03 mg/ml
- Accuracy: 97.03% (2.97% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/16178_CP3QFYCS786Z
- Originally Published: https://thinksteroids.com/community/posts/2970059/
Evaluation of Manufacturer-Funded Testing
Given that the test was both submitted and funded by the manufacturer, Driada Medical, it is vital to interpret the findings with caution. While the results demonstrate accurate dosing, independent third-party verification would further strengthen confidence in the product’s consistency and quality. Janoshik Analytical’s established reputation for reliable testing provides additional assurance.
Conclusion
The testing of PRIMOS 100 mg/ml verifies its composition and potency, with a measured concentration close to its labeled specification. This product meets acceptable dosing accuracy standards, contributing to transparency and harm reduction in the anabolic steroid market. Reports like these help users make evidence-based decisions regarding product quality and safety.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside independent results. Readers are encouraged to interpret this information responsibly.
